Flexion Therapeutics to Report First-Quarter 2017
Post# of 301275
BURLINGTON, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) announced today that it will host a conference call and webcast to provide an update on business operations and report its first-quarter 2017 financial results on Thursday, May 4, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID #11984746. A live webcast of the conference call can also be accessed through the “ Investors ” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA) of the knee. The company's lead product candidate, Zilretta TM (also known as FX006) is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 syoung@flexiontherapeutics.com
(0)
(0)